Cargando…
Potent inhibition of tumour cell proliferation and immunoregulatory function by mitochondria-targeted atovaquone
The FDA-approved prophylactic antimalarial drug atovaquone (ATO) recently was repurposed as an antitumor drug. Studies show that ATO exerts a profound antiproliferative effect in several cancer cells, including breast, ovarian, and glioma. Analogous to the mechanism of action proposed in parasites,...
Autores principales: | Cheng, Gang, Hardy, Micael, Topchyan, Paytsar, Zander, Ryan, Volberding, Peter, Cui, Weiguo, Kalyanaraman, Balaraman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578061/ https://www.ncbi.nlm.nih.gov/pubmed/33087770 http://dx.doi.org/10.1038/s41598-020-74808-0 |
Ejemplares similares
-
Mitochondria-targeted hydroxyurea inhibits OXPHOS and induces antiproliferative and immunomodulatory effects
por: Cheng, Gang, et al.
Publicado: (2021) -
Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferation
por: Cheng, Gang, et al.
Publicado: (2022) -
Prevention of Tumor Growth and Dissemination by In Situ Vaccination with Mitochondria‐Targeted Atovaquone
por: Huang, Mofei, et al.
Publicado: (2022) -
Antiproliferative effects of mitochondria-targeted N-acetylcysteine and analogs in cancer cells
por: Cheng, Gang, et al.
Publicado: (2023) -
Polyphenolic Boronates Inhibit Tumor Cell Proliferation: Potential Mitigators of Oxidants in the Tumor Microenvironment
por: Cheng, Gang, et al.
Publicado: (2023)